The company has not filed an annual or quarterly report since its Q2 FY2023 10-Q, filed Aug 11, 2023. Its latest SEC filing is a SC 13G/A from Feb 14, 2024.
10-Q for Q2 FY2023, filed Aug 11, 2023
The sections below describe the company as of the FY2022 annual report.
Develops gene therapies and a drug candidate for people with inherited or acquired hearing loss and balance disorders.
10-K for FY2022, filed Mar 14, 2023We are a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance…View ↗
We are also using our platform to design and develop a pipeline of gene therapies for hair cell regeneration within the inner ear. We are…View ↗
In addition to our gene therapy product candidates and programs, we are developing a clinical-stage product candidate, DB-020, for the…View ↗
No revenue was reported.
10-K for FY2022, filed Mar 14, 2023
10-Q for Q2 FY2023, filed Aug 11, 2023
−$18.1MView ↗
8-K, filed Sep 25, 2023
As described in the Introductory Note above, on September 25, 2023, Purchaser irrevocably accepted for payment all shares of Common Stock…View ↗
8-K, filed Aug 9, 2023
On August 8, 2023, Decibel Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the…View ↗
Competes with Akouos, Sensorion, Fennec Pharmaceuticals, and Sound Pharmaceuticals
10-K for FY2022, filed Mar 14, 2023Akouos, Inc., which is developing AK-OTOF, a gene therapy for profound hearing loss resulting from deficiency in OTOF, which is in clinical…View ↗
Loading...
